title: MSH3 rs26279 polymorphism increases cancer risk: a meta-analysis.
abstract: Previous studies have investigated the association of mutS homolog 3 (MSH3) rs26279 G > A polymorphism with the risk of different types of cancers including colorectal cancer, breast cancer, prostate cancer, bladder cancer, thyroid cancer, ovarian cancer and oesophageal cancer. However, its association with cancer remains conflicting. We performed a comprehensive meta-analysis to derive a more precise estimation of the relationship between MSH3 rs26279 G > A polymorphism and cancer susceptibility. Systematically searching the PubMed and EMBASE databases yielded 11 publications with 12 studies of 3282 cases and 6476 controls. The strength of the association was determined by crude odds ratios (OR) and 95% confidence intervals (CI). Overall, pooled risk estimates demonstrated that MSH3 rs26279 G > A was significantly associated with an increased overall cancer risk under all the genetic models (GG vs. AA: OR = 1.27, 95% CI = 1.09-1.48, P = 0.002; AG vs. AA: OR = 1.10, 95% CI = 1.00-1.21, P = 0.045; GG vs. AG + AA: OR = 1.23, 95% CI = 1.06-1.42, P = 0.005; AG + GG vs. AA: OR = 1.13, 95% CI = 1.04-1.24, P = 0.006; G vs. A: OR = 1.13, 95% CI = 1.05-1.20, P = 0.001). The association was more evident for colorectal cancer and breast cancer. Moreover, the significant association was also observed in the following subgroups: Europeans, Asians, population-based studies, hospital-based studies, and studies comprising relatively large sample size (≥ 200). Our meta-analysis results demonstrated that MSH3 rs26279 G > A polymorphism is associated with an increased risk of overall cancer, especially for the colorectal cancer and breast cancer.
authors.affiliation: Department of Clinical Laboratory, The 101th Hospital of The People's Liberation Army Wuxi 214044, Jiangsu, China.
authors.forename: Hui-Kai
authors.initials: HK
authors.lastname: Miao
authors.affiliation: Department of Clinical Laboratory, The 101th Hospital of The People's Liberation Army Wuxi 214044, Jiangsu, China.
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Chen
authors.affiliation: Department of Clinical Laboratory, The 101th Hospital of The People's Liberation Army Wuxi 214044, Jiangsu, China.
authors.forename: Dong-Ping
authors.initials: DP
authors.lastname: Cai
authors.affiliation: Department of Clinical Laboratory, The 101th Hospital of The People's Liberation Army Wuxi 214044, Jiangsu, China.
authors.forename: Wei-Ju
authors.initials: WJ
authors.lastname: Kong
authors.affiliation: Department of Clinical Laboratory, The 101th Hospital of The People's Liberation Army Wuxi 214044, Jiangsu, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xiao
authors.affiliation: Department of Clinical Laboratory, The 101th Hospital of The People's Liberation Army Wuxi 214044, Jiangsu, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Lin
mesh_terms: D004268:DNA-Binding Proteins / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D000074081:MutS Homolog 3 Protein; D009369:Neoplasms / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
chemical_list: D004268:DNA-Binding Proteins; C078444:MSH3 protein, human; D000074081:MutS Homolog 3 Protein
keywords: MSH3; cancer; meta-analysis; polymorphism